Coya Therapeutics

Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases

Sponsored

Positive Financials Along With Promising Clinical Results – Coya Therapeutics

Sponsored

Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?

Sponsored

Positive Financials Along With Promising Clinical Results – Coya Therapeutics

Sponsored

Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?

Sponsored

There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study

Sponsored

Coya Therapeutics: This BioPharma Company Has Some Big News To Share

Sponsored

There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study

Sponsored

Coya Therapeutics: This BioPharma Company Has Some Big News To Share

Sponsored

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development

Sponsored

Coya Therapeutics' COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study

Sponsored

Coya Therapeutics Recent News

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited.

Sponsored

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?

Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field.

Sponsored

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary investigational biologic combination at the 2023 MDA Clinical & Sci

Sponsored

Coya Therapeutics' Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments

Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available to more patients, as it announced the expansion of its exclusive worldwide rights for the development and c

Sponsored